biomarkers

Through academic, industry, and governmental partnerships, scientists validate and develop non-invasive diagnostics for non-alcoholic fatty liver disease. These tests are set to replace the invasive and risky gold standard: liver biopsy.

LIVE March 29th, 2022 at 2:30 PM
Proteolysis targeting chimeras (PROTACs) are promising agents for developing novel anticancer drugs.

A bioengineer mines the biometric data from smartwatches and smartphones to find digital biomarkers for respiratory infections like COVID-19.

Researchers are tapping into the regenerative power of stem cells to treat central nervous system disorders.

LIVE September 13th, 2021 at 11:00 AM ET
In this webinar, Shane Needham will discuss methods to optimize protein quantification workflows and introduce a new HRAMS system, the ZenoTOF 7600.   

High tumor mutation burden can predict immunotherapy response only in subset of cancers

NuView’s theranostics approach could make cancer diagnosis and treatment more affordable

Loss of endothelial function is induced through two different pathophysiological processes

Denali Therapeutics reports positive three-month data from Phase 1/2 study of DNL310 in patients with Hunter syndrome

Eurofins Viracor and Cleveland Clinic sign licensing agreement for exclusive rights to biomarker test for detecting kidney transplant rejection